LT3728271T - Makrocikliniai junginiai, skirti ligų gydymui - Google Patents

Makrocikliniai junginiai, skirti ligų gydymui

Info

Publication number
LT3728271T
LT3728271T LTEPPCT/US2018/066158T LTUS2018066158T LT3728271T LT 3728271 T LT3728271 T LT 3728271T LT US2018066158 T LTUS2018066158 T LT US2018066158T LT 3728271 T LT3728271 T LT 3728271T
Authority
LT
Lithuania
Prior art keywords
treating diseases
macrocyclic compounds
macrocyclic
compounds
diseases
Prior art date
Application number
LTEPPCT/US2018/066158T
Other languages
English (en)
Inventor
Evan W. ROGERS
Jingrong Jean Cui
Dayong Zhai
Han Zhang
Jane Ung
Wei Deng
Jeffrey WHITTEN
Original Assignee
Turning Point Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics, Inc. filed Critical Turning Point Therapeutics, Inc.
Publication of LT3728271T publication Critical patent/LT3728271T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2018/066158T 2017-12-19 2018-12-18 Makrocikliniai junginiai, skirti ligų gydymui LT3728271T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13
PCT/US2018/066158 WO2019126121A1 (en) 2017-12-19 2018-12-18 Macrocyclic compounds for treating disease

Publications (1)

Publication Number Publication Date
LT3728271T true LT3728271T (lt) 2022-12-12

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/066158T LT3728271T (lt) 2017-12-19 2018-12-18 Makrocikliniai junginiai, skirti ligų gydymui

Country Status (29)

Country Link
US (3) US10745416B2 (lt)
EP (2) EP3728271B1 (lt)
JP (2) JP7194188B2 (lt)
KR (1) KR102814342B1 (lt)
CN (1) CN111511746B (lt)
AU (1) AU2018392332B2 (lt)
BR (1) BR112020012319A2 (lt)
CA (1) CA3083674A1 (lt)
CL (1) CL2020001632A1 (lt)
CY (1) CY1125772T1 (lt)
DK (1) DK3728271T3 (lt)
EC (1) ECSP20033467A (lt)
ES (1) ES2929467T3 (lt)
HR (1) HRP20221502T1 (lt)
HU (1) HUE060711T2 (lt)
IL (1) IL275265B2 (lt)
JO (1) JOP20200152A1 (lt)
LT (1) LT3728271T (lt)
MX (1) MX2020006490A (lt)
PE (1) PE20200937A1 (lt)
PH (1) PH12020550901A1 (lt)
PL (1) PL3728271T3 (lt)
PT (1) PT3728271T (lt)
RS (1) RS63787B1 (lt)
SG (1) SG11202005590PA (lt)
SI (1) SI3728271T1 (lt)
SM (1) SMT202200443T1 (lt)
TW (1) TW201930312A (lt)
WO (1) WO2019126121A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
ES2898364T3 (es) 2017-12-19 2022-03-07 Bristol Myers Squibb Co Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257169A1 (en) 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
US11634433B2 (en) * 2019-12-03 2023-04-25 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
EP4163283A1 (en) 2020-06-04 2023-04-12 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
WO2023060022A1 (en) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthesis of macrocyclic compounds
EP4559919A1 (en) * 2022-07-22 2025-05-28 Medshine Discovery Inc. Tricyclic-containing macrocyclic compound and use thereof
EP4573095A1 (en) * 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
JP7571173B2 (ja) 2023-02-24 2024-10-22 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195935T1 (de) * 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
KR20110073500A (ko) 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
BR112013011520A2 (pt) * 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
US10457691B2 (en) * 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
WO2017148325A1 (zh) * 2016-03-03 2017-09-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
ES2898364T3 (es) 2017-12-19 2022-03-07 Bristol Myers Squibb Co Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
US11584759B2 (en) 2018-04-18 2023-02-21 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
MX2020006490A (es) 2020-08-17
KR20200101358A (ko) 2020-08-27
US11286265B2 (en) 2022-03-29
PL3728271T3 (pl) 2023-01-23
US20200190110A1 (en) 2020-06-18
CN111511746B (zh) 2024-01-09
IL275265B1 (en) 2023-03-01
EP3728271A4 (en) 2021-06-23
PE20200937A1 (es) 2020-09-17
KR102814342B1 (ko) 2025-05-29
CA3083674A1 (en) 2019-06-27
ECSP20033467A (es) 2020-09-30
HUE060711T2 (hu) 2023-04-28
CY1125772T1 (el) 2026-02-25
SMT202200443T1 (it) 2023-01-13
SI3728271T1 (sl) 2023-01-31
EP3728271B1 (en) 2022-09-28
JP2021506850A (ja) 2021-02-22
BR112020012319A2 (pt) 2020-11-24
US20200392160A1 (en) 2020-12-17
PH12020550901A1 (en) 2021-05-17
RS63787B1 (sr) 2022-12-30
ES2929467T3 (es) 2022-11-29
IL275265B2 (en) 2023-07-01
AU2018392332B2 (en) 2023-08-03
JP2023027237A (ja) 2023-03-01
TW201930312A (zh) 2019-08-01
SG11202005590PA (en) 2020-07-29
JP7194188B2 (ja) 2022-12-21
PT3728271T (pt) 2022-10-06
US20220306652A1 (en) 2022-09-29
HRP20221502T1 (hr) 2023-03-31
CN111511746A (zh) 2020-08-07
EP3728271A1 (en) 2020-10-28
AU2018392332A1 (en) 2020-06-11
EP4151641A1 (en) 2023-03-22
US10745416B2 (en) 2020-08-18
CL2020001632A1 (es) 2020-11-20
JOP20200152A1 (ar) 2022-10-30
WO2019126121A1 (en) 2019-06-27
DK3728271T3 (da) 2022-12-19
IL275265A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
LT3728271T (lt) Makrocikliniai junginiai, skirti ligų gydymui
SG11201705093UA (en) Composition for treating il-6-related diseases
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL249229A0 (en) Compounds for the treatment of brain cancer
HUE050567T2 (hu) Triciklusos heterociklusok rák kezelésére
IL251790A0 (en) Compounds include thiazole for the treatment of culture diseases
GB201709402D0 (en) Compounds for treating t-pll
GB201716942D0 (en) Therapeutic compounds
IL259297A (en) Heterocyclic compounds for the treatment of disease
ZA201906047B (en) Compounds for treating tuberculosis
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
ZA201704589B (en) Compounds for the treatment of cancer
EP3261635A4 (en) Compounds for treating ocular diseases
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
HK40036156A (en) Macrocyclic compounds for treating disease
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201715210D0 (en) Macrocyclic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712394D0 (en) Therapeutic compounds
GB201712395D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
EP3354271A4 (en) Agent for treating arthrological diseases